MHRA approves Sanofi Pasteur MSD’s four-strain influenza vaccine for UK use
July 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi pasteur msd, UK, Vaccine, flu, influenza
Sanofi Pasteur MSD has announced the approval of the latest addition to its family of influenza vaccines in the UK: …
Flawed studies at Semler Research Centre calls for suspension of medicines, EMA recommends
July 25, 2016Manufacturing and Production, Sales and Marketing EMA, Novartis, Teva, manufacturing, semler
Following an FDA inspection and WHO investigation earlier this year, the European Medicines Agency (EMA) has recommended the suspension of …
400 current and former employees join sexual discrimination lawsuit against MSD
July 25, 2016Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit
Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …
AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C
July 25, 2016Research and Development, Sales and Marketing EU, Gilead, Viekirax, hepatitis C
AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …
EU recommends PrEP in Gilead’s HIV prevention treatment
July 25, 2016Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention
Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …
Shire receives positive EU opinion for pancreatic cancer drug
July 25, 2016Research and Development, Sales and Marketing CHMP, EU, Pancreatic cancer, Shire
Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …
EMA recommends two new treatments for advanced kidney cancer
July 22, 2016Research and Development, Sales and Marketing EMA, Eisai, renal cell carcinoma
The European Medicines Agency (EMA) has recommended two new medicines for the treatment of advanced renal cell carcinoma, or kidney …
Valeant receives complete response letter from FDA on glaucoma drug
July 22, 2016Medical Communications, Sales and Marketing FDA, Glaucoma, Valeant
Valeant Pharmaceuticals has announced that it has received a complete response letter from the FDA rejecting their new drug application …
MSD faces delay in C. diff drug approval as FDA requests more data
July 22, 2016Medical Communications, Research and Development C diff, FDA, MSD, Merck
MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …
Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug
July 22, 2016Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001
Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …
Phase III study confirms similarity of Herceptin biosimilar from Amgen, Allergan
July 22, 2016Medical Communications, Research and Development Allergan, Amgen, Herceptin, Roche, biosimilar, trastuzumab
Amgen and Allergan have announced the results from a Phase III study investigating ABP 980, their biosimilar candidate for Roche’s …
George Scangos to step down as Biogen CEO
July 21, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, George Scangos
In a surprising move, Biogen used the publishing of some promising second quarter results to announce the departure of CEO …
AstraZeneca’s Zavicefta meets primary endpoint in Phase III pneumonia trials
July 21, 2016Research and Development Antibiotics, AstraZeneca, zavifecta
AstraZeneca has announced results from a Phase III trial for its recently approved antibiotic, Zavicefta (ceftazidime-avibactam), which met its primary …
Galenica announces $1.53 billion Replysa acquisition
July 21, 2016Research and Development, Sales and Marketing Relypsa, Vifor pharma, galenica
Galenica has announced that it has entered into an agreement to acquire Relypsa in a deal worth $1.53 billion, which …
Roche beats forecasts in strong H1 results
July 21, 2016Research and Development, Sales and Marketing 2016, Q2, Roche, h1, results
Roche has published very encouraging full results for the first half of this year, with cancer drug sales helping to …
Zafgen ends lead drug development, shares plummet
July 21, 2016Research and Development zafgen
Zafgen has announced that it has dropped development of its lead drug candidate, beloranib, in order to focus on a …
New Irish pharma deal to save €750 million, says minister
July 20, 2016Sales and Marketing Ireland, Irish Pharmaceutical Healthcare Association
The Irish government has struck a deal with pharmaceutical manufacturers regarding the price and supply of medicines, which is expected …
NICE recommends PTC Therapeutics Duchenne muscular dystrophy treatment
July 20, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics
PTC Therapeutics has announced that the National Institute for Health and Care Excellence has issued final guidance recommending Translarna (ataluren) …
AstraZeneca loses legal bid to block Crestor generics
July 20, 2016Research and Development, Sales and Marketing AstraZeneca, Crestor, FDA, generics, legal
A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …
J&J boosted by pharma revenue in Q2 results
July 20, 2016Research and Development 2016, Johnson and Johnson, Q2, results
Shares at Johnson and Johnson have reached a record high of over $125 after pharma revenues helped to raise full …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
